Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?

Pharmaceutical Development and Technology

Volumn 19, Issue 3, 2014, Pages 257-262

  Ohrem, H Leonhard ^a   Schornick, Eva ^a   Kalivoda, Adela ^a   Ognibene, Roberto ^a  

^a MERCK KGAA   (Germany)

Author keywords

Binder; Direct compression; Excipients; Filler; Incompatibility; Mannitol; Solid oral dosage forms; Stability; Tablet

Indexed keywords

CALCIUM HYDROGEN PHOSPHATE DIHYDRATE; CALCIUM PHOSPHATE; EXCIPIENT; FILLER; LACTOSE; MANNITOL; MICROCRYSTALLINE CELLULOSE; PHOSPHATE; UNCLASSIFIED DRUG;

DRUG DOSAGE FORM; DRUG FORMULATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLID; TECHNOLOGY; WETTABILITY;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HUMANS; MANNITOL; TABLETS;

EID: 84899837216     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.775154     Document Type: Review

References (42)

1. Paterson AHJ. Production and uses of lactose. In: McSweeney P, Fox PF, eds. Advanced dairy chemistry. New York: Springer; 2009:105-20.
2. Gordon J. Dairy products. In: Ranken MD, Kill RC, Baker CGJ, eds. Food industries manual. London: Blackie Academic & Professional; 1997:75-138.
3. Yoshinari T, Forbes RT, York P, Kawashima Y. The improved compaction properties of mannitol after a moisture-induced polymorphic transition. Int J Pharm 2003;258:121-31.
4. ICH. ICH harmonised tripartite guideline. Stability testing of new drug substances and products Q1A(R2); 2003.
5. Brandstetter R, Conetta R, Glazer B. Lactose intolerance associated with Intal capsules. N Engl J Med 1986;315:1613-14.
6. Zumbé A, Lee A, Storey D. Polyols in confectionery: the route to sugar-free, reduced sugar and reduced calorie confectionery. Br J Nutr 2001;85:S31-45.
7. Gudmand-Hoyer E, Simony K. Individual sensitivity to lactose in lactose malabsorption. Am J Dig Dis 1977;22:177-81.
8. Petrini L, Usai P, Caradonna A, et al. Lactose intolerance following antithyroid drug medications. J Endocrinol Invest 1997;20:569-70.
9. Bedine M, Bayless T. Intolerance of small amounts of lactose by individuals with lowlactase levels. Gastroenterology 1973;65:735-43.
10. Zarbock S, Magnuson B, Hoskins L, et al. Lactose: the hidden culprit in medication intolerance? Orthopedics 2007;30:615-17.
11. Vesa TH, Marteau P, Korpela R. Lactose intolerance. J Am Coll Nutr 2000;19:165S-75S.
12. Born P. Carbohydrate malabsorption in patients with non-specific abdominal complaints. World J Gastroenterol 2007;13:5687-91.
13. Eadala P, Waud JP, Matthews SB, et al. Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther 2009;29:677-87.
14. Picksak G, Stichtenoth DO. Tablets containing lactose in lactose intolerance? [Lactosehaltige Tabletten bei Lactose-Intoleranz?] Med Monatsschr Pharm 2009;32:27-8.
15. Gibson PR, Newnham E, Barrett JS, et al. Review article: fructose malabsorption and the bigger picture. Aliment Pharmacol Ther 2007;25:349-63.
16. Peters R, Lock RH. Laxative effect of sorbitol. Br Med J 1958;2: 677-8.
17. EMA. Public report: risk an regulatory assessment of lactose and other products prepared using calf rennet. London: EMA; 2002.
18. European Commission-Enterprise Directorate-General. Volume 3B Guidelines: Medicinal products for human use-safety, environment and information: excipients in the label and package leaflet of medicinal products for human use. Brussels: Author; 2003.
19. Dills Jr WL. Sugar alcohols as bulk sweeteners. Annu Rev Nutr 1989;9:161-86.
20. Le Bot Y, Gouy PA. Polyols from starch. In: Kearsley MW, Dziedzic SZ, eds. Handbook of starch hydrolysis products and their derivatives. London: Chapman & Hall, 1995:155-77.
21. Menzies IS, Jenkins AP, Heduan E, et al. The effect of poorly absorbed solute on intestinal absorption. Scand J Gastroenterol 1990;25:1257-64.
22. Schiweck H, Ziesenitz S. Physiological properties of polyols in comparison with easily metabolisable saccharides. In: Grenby TH, ed. Advances in sweeteners. London: Chapman & Hall, 1996:56-84.
23. Debord B, Lefebvre C, Guyot-Hermann AM, et al. Study of different crystalline forms of mannitol: comparative behaviour under compression. Drug Dev Ind Pharm 1987;13:1533-46.
24. Geil PB. Complex and simple carbohydrates in diabetes therapy. In: Powers Ma, ed. Handbook of diabetes medical nutrition therapy. Gaithersburg: Aspen Publishers, 1996:303-17.
25. Bharate SS, Bharateb SB, Bajajc AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excipients and Food Chem 2010;1:3-26.
26. Flemming A, Picker-Freyer KM. Compaction of lactose drug mixtures: quantification of the extent of incompatibility by FTRaman spectroscopy. Eur J Pharm Biopharm 2008;68:802-10.
27. Doldán C, Souto C, Concheiro A, et al. Dicalcium phosphate dihydrate and anhydrous dicalcium phosphate for direct compression: A comparative study. Int J Pharm 1995;124:69-74.
28. Carstensen JT, Ertell C. Physical and chemical properties of calcium phosphates for solid state pharmaceutical formulations. Drug Dev Ind Pharm 1990;16:1121-33.
29. Wu Y, Levons J, Narang AS, et al. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility. AAPS PharmSciTech 2011;12:1248-63.
30. DeMerlis CC. Regulation of pharmaceutical excipients. In: Weiner ML, Kotkoskie LA, eds. Excipient toxicity and safety. New York: Marcel Dekker, 1999:73-100.
31. Narang A, Desai D, Badawy S. Impact of excipient interactions on solid dosage form stability. Pharm Res 2012;29:2660-83.
32. Lee C. Addressing drug-excipient interactions. In: Nickerson B, ed. Sample preparation of pharmaceutical dosage forms: challenges and strategies for sample preparation and extraction. New York: Springer; 2011:131-43.
33. Yu H, Cornett C, Larsen J, Hansen SH. Reaction between drug substances and pharmaceutical excipients: formation of esters between cetirizine and polyols. J Pharm Biomed Anal 2010;53: 745-50.
34. Okada S, Nakahara H, Isaka H. Adsorption of drugs on microcrystalline cellulose suspended in aqueous solutions. Chem Pharm Bull 1987;35:761-8.
35. Al-Nimry SS, Assaf SM, Jalal IM, Najib NM. Adsorption of ketotifen onto some pharmaceutical excipients. Int J Pharm 1997; 149:115-21.
36. Bolhuis GK, Anthony Armstrong N. Excipients for direct compaction-an update. Pharm Dev Technol 2006;11:111-24.
37. Zhang Y, Law Y, Chakrabarti S. Physical properties and compact analysis of commonly used direct compression binders. AAPS PharmSciTech 2003;4:489-99.
38. Narayan P, Hancock BC. The relationship between the particle properties, mechanical behavior, and surface roughness of some pharmaceutical excipient compacts. Mater Sci Eng, A 2003;355: 24-36.
39. Badawy SIF, Shah KR, Surapaneni MS, et al. Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation. Pharm Dev Technol 2010;15: 339-45.
40. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharm Technol 2003;27:92-100.
41. Shukla D, Chakraborty S, Singh S, Mishtra B. Mouth dissolving tablets I: an overview of formulation technology. Sci Pharm 2009; 77:309-26.
42. Duriez X, Joshi AA. Starches A versatile source. Pharma Form Qual 2004;6:48-50.